Other

University of Kentucky Research Foundation

Targacept, Inc.

Alain Ravard

Peter Anthony Crooks

Gary Maurice Dull

William Scott Caldwell

Balwinder Singh Bhatti

Niranjan Madhukar Deo

Linda P Dwoskin

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo&lsqb;2.2.1&rsqb;heptane, a 1-aza-2-(3-pyridyl)bicyclo &lsqb;2.2.2&rsqb;octane, a 1-aza-2-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane, a 1-aza-7-(3-pyridyl) bicyclo&lsqb;2.2.1&rsqb;heptane, a 1-aza-3-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane, or a 1-aza-7-(3-pyridyl)bicyclo&lsqb;3.2.2&rsqb;nonane.

Pharmaceutical compositions for treating and/or preventing CNS disorders

Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.

Pharmaceutical compositions for prevention and treatment of central

Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.

Nicotinic receptor antagonists in the treatment of neuropharmacological

Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.

Growing community of inventors

Lexington, KY, United States of America

Alain Ravard